Targeted Tx for AML

CE

Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Released: January 06, 2022

Expiration: January 05, 2023

Sara Tinsley-Vance
Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Activity

Progress
1
Course Completed

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:

  • Approved and emerging treatment options for FLT3-mutated AML
  • Management of adverse events associated with FLT3 inhibitors
  • Therapies for IDH1- and IDH2-mutated AML
  • Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors